To Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of JSI-1187 Capsule in the Treatment of Advanced Solid Tumors With MAPK Signaling Pathway Mutations
Latest Information Update: 09 Jul 2024
At a glance
- Drugs JSI-1187 (Primary)
- Indications Cholangiocarcinoma; Colorectal cancer; Gallbladder cancer; Head and neck cancer; Solid tumours
- Focus Adverse reactions
- Sponsors JS InnoPharm (Shanghai)
- 04 Jun 2024 Results assessing the safety and efficacy of ERK Inhibitor JSI-1187 for advanced MAPK-mutant tumors patients presented at the 60th Annual Meeting of the American Society of Clinical Oncology
- 06 Feb 2024 New trial record